Summary
A 23-year-old research analyst was granted his initial security clearance despite past marijuana use, which was evaluated under Guideline H (Drug Involvement). The applicant admitted to using marijuana approximately 20 times between March 2007 and February 2010, with five instances occurring after he began working for a defense contractor. He also acknowledged purchasing marijuana. These actions raised disqualifying conditions under Guideline H.
However, the judge applied mitigating conditions, finding that the applicant had demonstrated a commitment to abstain from future illegal drug use. He fully disclosed his past drug use during the security clearance application process and subsequent interview. Furthermore, his employer and family expressed support, indicating their trust in his integrity.
Ultimately, the judge determined that the applicant's past behavior had not affected his professional responsibilities and that he had made a clear commitment to abstinence. Based on these factors, the security clearance was granted.
Why the Applicant Prevailed
- The applicant demonstrated a commitment to abstain from illegal drug use in the future.
- He disclosed his past drug use during the security clearance application process and subsequent interview.
- The applicant's employer and family supported him, indicating trust in his integrity.
Conditions Referenced
- AG ¶ 25(a)raisedAny Drug Abuse
- AG ¶ 25(c)raisedIllegal Drug Possession
- AG ¶ 26(b)(4)appliedA Signed Statement of Intent with Automatic Revocation of Clearance for Any Violation
- AG ¶ 26(b)(2)appliedChanging or Avoiding the Environment Where Drugs Were Used
Key Rule Quoted
“The protection of the national security is the paramount consideration.”
Procedural Posture
- SOR issuedSep 22, 2010
- Answer filedOct 14, 2010
- Hearing heldJan 26, 2011
- Decision dateFeb 16, 2011
Cite For
- Demonstrated Intent Not to Abuse Drugs in the Future Under Guideline H
- Importance of Full Disclosure in Security Clearance Applications
- Support From Employers and Family as a Mitigating Factor in Drug Involvement Cases